Emerging drugs for adrenocortical carcinoma
- 2 September 2008
- journal article
- review article
- Published by Informa Healthcare in Emerging Drugs
- Vol. 13 (3), 497-509
- https://doi.org/10.1517/14728214.13.3.497
Abstract
Adrenocortical carcinoma (ACC) is an extremely rare aggressive disease. Few data are available on the efficacy of systemic antineoplastic treatments (mitotane and cytotoxic therapy) in the treatment of advanced disease. this paper will review the existing treatment strategies and new perspectives in the management of ACC patients. An ongoing randomized international trial aims to define the best combination chemotherapy plus mitotane regimen. Based on the results of a case control study, mitotane is being explored as adjuvant therapy. Genetic and biological studies have identified molecular targets for specific targeted drugs such as IGF receptor inhibitors and antiangiogenetic drugs. Phase II trials are exploring the activity of these drugs either alone or in combination with chemotherapy.Keywords
This publication has 63 references indexed in Scilit:
- Platinum Resistance: The Role of DNA Repair PathwaysClinical Cancer Research, 2008
- Adrenocortical cancer: pathophysiology and clinical managementEndocrine-Related Cancer, 2007
- Adrenocortical CarcinomaSurgical Oncology Clinics of North America, 2006
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacyEuropean Journal Of Cancer, 2004
- An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinomaProceedings of the National Academy of Sciences, 2001
- Adrenocortical Carcinoma: Experience in 45 PatientsOncology, 1997
- The Italian registry for adrenal cortical carcinoma: Analysis of a multiinstitutional series of 129 patientsSurgery, 1996
- Surgical management, DNA content, and patient survival in adrenal cortical carcinomaSurgery, 1995
- Clinical Features of Adrenocortical Carcinoma, Prognostic Factors, and the Effect of Mitotane TherapyNew England Journal of Medicine, 1990